Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Ensysce Biosciences, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −5 vs. Q3 2022
- Shares held
- 184.8K
- −3.60M (−95.1%) vs. Q3 2022
- Total value
- $138.2K
- −$694.5K (−83.4%) vs. Q3 2022
- New holders
- 7
- 1 more added
- Sold out
- 12
- 6 more reduced
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $832.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 42,277 | $31.7K | 0.00% | +42,277 | New |
| Two Sigma Investments, LP | 39,870 | $29.9K | 0.00% | +39,870 | New |
| Acadian Asset Management LLC | 26,602 | $19.0K | 0.00% | +26,602 | New |
| Susquehanna International Group, LLP | 17,649 | $13.2K | 0.00% | +17,649 | New |
| Millennium Management LLC | 14,438 | $11.0K | 0.00% | +14,438 | New |
| UBS Group AG | 13,884 | $10.4K | 0.00% | −38,258−73.4% | Reduced |
| BlackRock Inc. | 11,712 | $8.78K | 0.00% | −222,528−95.0% | Reduced |
| Stifel Financial Corp | 10,832 | $8.12K | 0.00% | −205,810−95.0% | Reduced |
| Bank of America Corp | 6,051 | $4.54K | 0.00% | +6,051 | New |
| Tower Research Capital LLC (TRC) | 760 | $1.00K | 0.00% | −14,673−95.1% | Reduced |
| Morgan Stanley | 276 | $207 | 0.00% | +273+9,100.0% | Added |
| Plante Moran Financial Advisors, LLC | 248 | $186 | 0.00% | +248 | New |
| Wolverine Asset Management LLC | 150 | $112 | 0.00% | −4,837−97.0% | Reduced |
| Wells Fargo & Company | 8 | $6 | 0.00% | −143−94.7% | Reduced |
| HG Vora Capital Management, LLC | 0 | $0 | 0.00% | −2,462,500−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −315,828−100.0% | Sold out |
| Cerity Partners LLC | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −130,523−100.0% | Sold out |
| Moneta Group Investment Advisors LLC | 0 | $0 | 0.00% | −5,116−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −51,089−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −41,789−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −35,551−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −33,994−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −20,431−100.0% | Sold out |
| StoneX Group Inc. | 0 | $0 | 0.00% | −12,781−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Covington Capital Management | – | – | – | – | Not filed |